On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

UPDATED: AbbVie wins blockbuster hep C approval, but shuns a deep discount on price

AbbVie won an expected FDA approval for its next-generation treatment for hepatitis C, kicking off a race with Gilead Sciences for dominance in a blockbuster field.

FDA approves Viekira Pak to treat hepatitis C

The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus...

AstraZeneca grabs a surprise early approval for its $2B cancer contender

Despite loud objections from its advisers, the FDA granted an accelerated approval to AstraZeneca's ovarian cancer treatment, clearing an oral therapy the U.K. drugmaker believes will bring in blockbuster sales.

FDA approves Lynparza to treat advanced ovarian cancer

The U.S. Food and Drug Administration today granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as...

Ascendis swings for an $86M IPO; Zymeworks banks $4M for bispecific antibody R&D;

@FierceBiotech: Juno banks $265M in an IPO, pushing the next big thing in oncology. Story | Follow @FierceBiotech @JohnCFierce: You want to start an argument? Walk into a room full of neuroscientists...

The Fonds de solidarité FTQ Invests $4 Million in Zymeworks Inc. in Support of Québec's Health Sciences Sector

MONTRÉAL, Canada & VANCOUVER, Canada--The Fonds de solidarité FTQ, a Québec-based development capital fund, today announced an investment of $4 million in common shares of...

ImmunoGen Reports Roche Has Provided an Update on the MARIANNE Trial

WALTHAM, Mass.-- ImmunoGen, Inc. (IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported that Roche has...

Gilead buys into Ono's cancer drug as it scales up in oncology

Gilead Sciences is pushing further into oncology R&D, teaming up with Ono Pharmaceutical on a cancer treatment that could complement its first major success in the field.

Acesion Pharma raises 15.2 million DKK in new equity from Novo A/S and Broadview Ventures.

Acesion Pharma, a Danish biotech company developing novel therapeutic treatments for atrial fibrillation (AF), today announced that it has raised 15.2 million DKK (2.5 million USD) in a new equity...